| ASD | Anti-seizure drug |
| AKT | Protein kinase B (PKB) |
| APDS | Activated phosphoinositide 3-kinase δ syndrome |
| BRRS | Bannayan-Riley-Ruvalcaba-Syndrom |
| CLL | Chronic lymphatic leukemia |
| CLOVES | congenital lipomatous overgrowth with vascular, epidermal, and skeletal anomalies |
| CNS | Central nervous system |
| CS | Cowden Syndrome |
| FCD | Focal Cortical Dysplasia |
| FCM | Focal cortical malformation |
| GOF | Gain of Function |
| GPCR | G protein-coupled receptor |
| LOF | Loss of Function |
| MCAP | megalencephaly capillary malformation |
| mTOR | Mammalian target of rapamycin |
| PI3K | Phosphatidyl inositol-3-kinase |
| PIP2 | Phosphatidylinositolbisphosphate |
| PK | Pharmacokinetic |
| PROS | PIK3CA-related overgrowth spectrum |
| PTEN | Phosphatase And Tensin Homolog |
| RTK | Receptor tyrosine kinase |
| SEGA | Subependymal giant cell astrocytoma |
| TAND | TSC-associated neuropsychiatric disorders |
| TORKi | mTOR kinase inhibitor |
| TSC | Tuberous Sclerosis Complex |